We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+31.13%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$4.73B
AUM Growth
+$575M
Cap. Flow
-$244M
Cap. Flow %
-5.15%
Top 10 Hldgs %
46.08%
Holding
127
New
17
Increased
23
Reduced
25
Closed
19
Avg Time Held Equity + Options
7.6 quarters
Top 10 Avg Time Held Equity + Options
6.2 quarters
Top 20 Avg Time Held Equity + Options
5.8 quarters
Avg Time Held Equity only
8 quarters
Top 10 Avg Time Held Equity only
6.2 quarters
Top 20 Avg Time Held Equity only
5.8 quarters

Top Buys

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$95.5M
2
VKTX icon
Viking Therapeutics
VKTX
+$57.4M
3
ARGX icon
argenx
ARGX
+$52.2M
4
ADGM icon
Adagio Medical Holdings
ADGM
+$46.7M
5
ORKA icon
Oruka Therapeutics
ORKA
+$43M

Top Sells

Rank Stock Value
1
CERE icon
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$441M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$74.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$60M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$38.8M
5
SWTX icon
SpringWorks Therapeutics
SWTX
+$35.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.6%
2 Miscellaneous 1.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ACLX icon
1
DELISTED
Arcellx
ACLX
$325M 6.87%
3,888,669
-1,070
-0% -$71.3K
2022 Q2
9 quarters
NUVL icon
2
DELISTED
Nuvalent
NUVL
$305M 6.45%
2,979,235
+430,158
+17% +$35.7M
2021 Q3
12 quarters
FOLD icon
3
DELISTED
Amicus Therapeutics
FOLD
$300M 6.34%
28,057,456
– –
2014 Q1
42 quarters
IOVA icon
4
Iovance Biotherapeutics
IOVA
$6.6B
$250M 5.29%
26,617,709
+684,567
+3% +$6.49M
2015 Q1
38 quarters
PCVX icon
5
Vaxcyte
PCVX
$11B
$232M 4.9%
2,027,608
+165,000
+9% +$14.9M
2022 Q4
7 quarters
RYTM icon
6
Rhythm Pharmaceuticals
RYTM
$6.18B
$187M 3.95%
3,560,214
+113,635
+3% +$5.44M
2023 Q3
4 quarters
VRNA
7
DELISTED
Verona Pharma
VRNA
$182M 3.84%
6,315,933
+3,882,208
+160% +$95.5M
2020 Q3
16 quarters
SLNO icon
8
DELISTED
Soleno Therapeutics
SLNO
$162M 3.42%
3,204,976
– –
2023 Q2
5 quarters
ITCI icon
9
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$119M 2.51%
1,622,215
-94,192
-5% -$7.08M
2023 Q4
3 quarters
APGE icon
10
DELISTED
Apogee Therapeutics
APGE
$118M 2.5%
2,015,007
-90,629
-4% -$4.34M
2023 Q3
4 quarters
VKTX icon
11
Viking Therapeutics
VKTX
$3.6B
$108M 2.28%
1,699,987
+978,610
+136% +$57.4M
2024 Q1
2 quarters
CNTA
12
DELISTED
Centessa Pharmaceuticals
CNTA
$100M 2.13%
6,282,290
+2,348,983
+60% +$28.8M
2024 Q1
2 quarters
IMTX icon
13
Immatics
IMTX
$1.1B
$92.3M 1.95%
8,086,159
– –
2020 Q3
16 quarters
EOLS icon
14
Evolus
EOLS
$512M
$86.8M 1.84%
5,356,622
-397,176
-7% -$5.55M
2023 Q3
4 quarters
SYRE icon
15
Spyre Therapeutics
SYRE
$8.03B
$84.5M 1.79%
2,872,547
-158,471
-5% -$4.41M
2023 Q3
4 quarters
AORT icon
16
Artivion
AORT
$1.06B
$74.4M 1.57%
2,793,703
– –
2021 Q4
11 quarters
BHVN icon
17
Biohaven
BHVN
$1.78B
$74.2M 1.57%
1,485,232
– –
2023 Q2
5 quarters
ATXS icon
18
DELISTED
Astria Therapeutics
ATXS
$71.4M 1.51%
6,485,420
– –
2021 Q1
14 quarters
AXSM icon
19
Axsome Therapeutics
AXSM
$8.7B
$70.4M 1.49%
782,844
+323,733
+71% +$28.3M
2023 Q2
5 quarters
APLT icon
20
DELISTED
Applied Therapeutics
APLT
$68M 1.44%
8,005,000
– –
2023 Q4
3 quarters
CRGX icon
21
DELISTED
CARGO Therapeutics
CRGX
$68M 1.44%
3,683,004
– –
2023 Q4
3 quarters
IMVT icon
22
Immunovant
IMVT
$6.09B
$67.8M 1.43%
2,378,762
+454,976
+24% +$13.4M
2022 Q4
7 quarters
PRAX icon
23
Praxis Precision Medicines
PRAX
$7.02B
$67M 1.42%
1,164,035
+413,805
+55% +$22.4M
2024 Q1
2 quarters
ARGX icon
24
argenx
ARGX
$51.1B
$64.4M 1.36%
118,839
+103,239
+662% +$52.2M
2024 Q2
1 quarter
VRDN icon
25
Viridian Therapeutics
VRDN
$2.07B
$64M 1.35%
2,812,665
+1,180,837
+72% +$19.3M
2021 Q2
13 quarters
1
2 3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Perceptive Advisors held 127 positions worth $4.73B, up 14% from $4.15B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors withdrew a net $244M in Q3 2024, closing 19 positions and reducing 25 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $441M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Perceptive Advisors opened a new position in Adagio Medical Holdings worth $25.3M.

  • Perceptive Advisors's largest Q3 2024 buy was Adagio Medical Holdings: 9,812,419 shares worth $25.3M.
  • Perceptive Advisors added most to Verona Pharma in Q3 2024, an estimated $95.5M increase.
  • Perceptive Advisors's biggest Q3 2024 reduction was Neurocrine Biosciences, cutting an estimated $60M.
  • Perceptive Advisors fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $441M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $4.73B portfolio in Q3 2024.
  • Perceptive Advisors opened 17 new positions and closed 19 in Q3 2024.
  • Perceptive Advisors's portfolio value rose 14% quarter-over-quarter to $4.73B.

Based on Perceptive Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.